Latest News and Press Releases

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium

Curium announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop).

Curium announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer.

ST. LOUIS, Mo., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that it has completed enrollment of its Phase 3 SOLAR-RECUR clinical trial. The trial is a...

ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center,...

*שיתוף פעולה שיכלול פיתוח קליני, הגשה רגולטורית ומסחור ביפן של 177Lu-PSMA-I&T ו- 64Cu-PSMA-I&T *מתבסס על מערכת יחסים ארוכת שנים בין שתי החברות *ביפן מאובחנים מדי שנה כ-90,000 מקרים חדשים...

此次合作将涵盖在日本开展的 177Lu-PSMA-I&T 和 64Cu-PSMA-I&T 的临床开发、监管备案及商业化进程这一合作建立在两家公司长期以来的紧密关系之上在日本，每年约有 90,000 例新诊断的前列腺癌病例 巴黎, Oct. 02, 2024 (GLOBE NEWSWIRE) -- 全球核医学领域的领先企业 Curium 今日宣布与 PeptiDream...

合作內容包括 177Lu-PSMA-I&T 和 64Cu-PSMA-I&T 在日本的臨床開發、監管備案和商業化工作基於兩間公司的長期合作關係日本每年有大約 9 萬宗前列腺癌新病例確診 巴黎, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Curium 是一家世界領先的核醫學企業，今天宣布與 PeptiDream 的全資子公司...

Kerja sama mencakup pengembangan klinis, pengajuan regulasi, dan komersialisasi di Jepang untuk 177Lu-PSMA-I&T dan 64Cu-PSMA-I&TDibangun di atas hubungan yang telah terjalin lama antara kedua...

Kolaborasi untuk menyertakan pembangunan klinikal, pemfailan kawal selia dan pengkomersialan di Jepun bagi 177Lu-PSMA-I&T dan 64Cu-PSMA-I&TDibina berdasarkan hubungan yang sudah lama terjalin...